Research ExplorerPublicationsPrevalence of circulating tumor cells in early breast cancer...

Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment

Standard

Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment. / Bauer, Emanuel C A; Schochter, Fabienne; Widschwendter, Peter; DeGregorio, Amelie; Andergassen, Ulrich; Friedl, Thomas W P; Fasching, Peter A; Fehm, Tanja; Schneeweiss, Andreas; Beckmann, Matthias W; Pantel, Klaus; Janni, Wolfgang; Rack, Brigitte; Scholz, Christoph; SUCCESS Study Group.

In: BREAST CANCER RES TR, Vol. 171, No. 3, 10.2018, p. 571-580.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bauer, ECA, Schochter, F, Widschwendter, P, DeGregorio, A, Andergassen, U, Friedl, TWP, Fasching, PA, Fehm, T, Schneeweiss, A, Beckmann, MW, Pantel, K, Janni, W, Rack, B, Scholz, C & SUCCESS Study Group 2018, 'Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment', BREAST CANCER RES TR, vol. 171, no. 3, pp. 571-580. https://doi.org/10.1007/s10549-018-4856-1

APA

Bauer, E. C. A., Schochter, F., Widschwendter, P., DeGregorio, A., Andergassen, U., Friedl, T. W. P., Fasching, P. A., Fehm, T., Schneeweiss, A., Beckmann, M. W., Pantel, K., Janni, W., Rack, B., Scholz, C., & SUCCESS Study Group (2018). Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment. BREAST CANCER RES TR, 171(3), 571-580. https://doi.org/10.1007/s10549-018-4856-1

Vancouver

Bauer ECA, Schochter F, Widschwendter P, DeGregorio A, Andergassen U, Friedl TWP et al. Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment. BREAST CANCER RES TR. 2018 Oct;171(3):571-580. https://doi.org/10.1007/s10549-018-4856-1

Bibtex

@article{dba47a10ed06464187268c89c063fe28,
title = "Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment",
abstract = "PURPOSE: Several studies have provided evidence on the prognostic relevance of circulating tumor cells (CTCs) detected before and after chemotherapy regarding overall survival (OS) and progression-free survival (PFS) in early breast cancer (EBC). We provide data on the prevalence of CTCs 2 and 5 years after primary diagnosis in a cohort of patients with EBC.METHODS: The SUCCESS study is a multicenter, prospective, randomized trial comparing PFS in primary breast cancer patients undergoing one of two adjuvant chemotherapy regimens followed by 2 versus 5 years of treatment with zoledronate. CTCs from patients without signs of breast cancer recurrence were analyzed in peripheral blood using the FDA cleared CellSearch{\textregistered} System (Veridex, USA) 2 and 5 years after primary diagnosis.RESULTS: CTCs were detected at 2 and 5 years after primary diagnosis in 96 (16.7%) and 47 (8.2%) of the 574 patients, respectively. There were no associations between CTC status and patient and tumor characteristics or treatment regimens. In 442 (77.0%) patients, no CTCs were detected at either of the two time points, and in 11 patients (1.9%), CTCs were found at both 2 and 5 years after primary diagnosis. In 85 (14.8%) patients, CTCs were present 2 years after primary diagnosis but not after 5 years, while 36 (6.3%) patients had CTCs in their blood only at the 5-year follow-up.CONCLUSIONS: In patients with EBC, CTCs can be detected even 5 years after primary diagnosis without clinical signs of disease recurrence.",
keywords = "Journal Article",
author = "Bauer, {Emanuel C A} and Fabienne Schochter and Peter Widschwendter and Amelie DeGregorio and Ulrich Andergassen and Friedl, {Thomas W P} and Fasching, {Peter A} and Tanja Fehm and Andreas Schneeweiss and Beckmann, {Matthias W} and Klaus Pantel and Wolfgang Janni and Brigitte Rack and Christoph Scholz and {SUCCESS Study Group}",
year = "2018",
month = oct,
doi = "10.1007/s10549-018-4856-1",
language = "English",
volume = "171",
pages = "571--580",
journal = "BREAST CANCER RES TR",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

RIS

TY - JOUR

T1 - Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment

AU - Bauer, Emanuel C A

AU - Schochter, Fabienne

AU - Widschwendter, Peter

AU - DeGregorio, Amelie

AU - Andergassen, Ulrich

AU - Friedl, Thomas W P

AU - Fasching, Peter A

AU - Fehm, Tanja

AU - Schneeweiss, Andreas

AU - Beckmann, Matthias W

AU - Pantel, Klaus

AU - Janni, Wolfgang

AU - Rack, Brigitte

AU - Scholz, Christoph

AU - SUCCESS Study Group

PY - 2018/10

Y1 - 2018/10

N2 - PURPOSE: Several studies have provided evidence on the prognostic relevance of circulating tumor cells (CTCs) detected before and after chemotherapy regarding overall survival (OS) and progression-free survival (PFS) in early breast cancer (EBC). We provide data on the prevalence of CTCs 2 and 5 years after primary diagnosis in a cohort of patients with EBC.METHODS: The SUCCESS study is a multicenter, prospective, randomized trial comparing PFS in primary breast cancer patients undergoing one of two adjuvant chemotherapy regimens followed by 2 versus 5 years of treatment with zoledronate. CTCs from patients without signs of breast cancer recurrence were analyzed in peripheral blood using the FDA cleared CellSearch® System (Veridex, USA) 2 and 5 years after primary diagnosis.RESULTS: CTCs were detected at 2 and 5 years after primary diagnosis in 96 (16.7%) and 47 (8.2%) of the 574 patients, respectively. There were no associations between CTC status and patient and tumor characteristics or treatment regimens. In 442 (77.0%) patients, no CTCs were detected at either of the two time points, and in 11 patients (1.9%), CTCs were found at both 2 and 5 years after primary diagnosis. In 85 (14.8%) patients, CTCs were present 2 years after primary diagnosis but not after 5 years, while 36 (6.3%) patients had CTCs in their blood only at the 5-year follow-up.CONCLUSIONS: In patients with EBC, CTCs can be detected even 5 years after primary diagnosis without clinical signs of disease recurrence.

AB - PURPOSE: Several studies have provided evidence on the prognostic relevance of circulating tumor cells (CTCs) detected before and after chemotherapy regarding overall survival (OS) and progression-free survival (PFS) in early breast cancer (EBC). We provide data on the prevalence of CTCs 2 and 5 years after primary diagnosis in a cohort of patients with EBC.METHODS: The SUCCESS study is a multicenter, prospective, randomized trial comparing PFS in primary breast cancer patients undergoing one of two adjuvant chemotherapy regimens followed by 2 versus 5 years of treatment with zoledronate. CTCs from patients without signs of breast cancer recurrence were analyzed in peripheral blood using the FDA cleared CellSearch® System (Veridex, USA) 2 and 5 years after primary diagnosis.RESULTS: CTCs were detected at 2 and 5 years after primary diagnosis in 96 (16.7%) and 47 (8.2%) of the 574 patients, respectively. There were no associations between CTC status and patient and tumor characteristics or treatment regimens. In 442 (77.0%) patients, no CTCs were detected at either of the two time points, and in 11 patients (1.9%), CTCs were found at both 2 and 5 years after primary diagnosis. In 85 (14.8%) patients, CTCs were present 2 years after primary diagnosis but not after 5 years, while 36 (6.3%) patients had CTCs in their blood only at the 5-year follow-up.CONCLUSIONS: In patients with EBC, CTCs can be detected even 5 years after primary diagnosis without clinical signs of disease recurrence.

KW - Journal Article

U2 - 10.1007/s10549-018-4856-1

DO - 10.1007/s10549-018-4856-1

M3 - SCORING: Journal article

C2 - 29931425

VL - 171

SP - 571

EP - 580

JO - BREAST CANCER RES TR

JF - BREAST CANCER RES TR

SN - 0167-6806

IS - 3

ER -